Summary
A multicentre, randomised, controlled study compared the efficacy of l-α-glyceryl-phosphorylcholine (αGPC) and ST200 (acetyl-l-carnitine) among 126 patients with probable senile dementia of Alzheimer’s type (SDAT) of mild to moderate degree. Efficacy was evaluated by means of behavioural scales and psychometric tests. The results showed significant improvements in most neuropsychological parameters in the αGPC recipients. Improvements also occurred in the ST200 recipients but to a lesser extent. Tolerability was good in both groups. These positive findings require replication in larger, double-blind, longitudinal studies coupling clinical and biological determinations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Calvani M, Carta A. Clues to the mechanism of action of acetyl-L-carnitine in the central nervous system. Dementia 2: 1–6, 1991
Cucinotta D, Passen M, Ventura S, Iannuccelli M, Senin U, et al. Multicenter clinical placebo-controlled study with acetyl-L-carnitine in the treatment of mildly demented elderly patients. Drug Developmental Research 14: 213–216, 1988
Di Perri R, Coppola G, Ambrosio LA, Grasso A, Puca FM, et al. A multicentre trial to evaluate the efficacy and tolerability of α-glycerylphosphorylcholine versus cytidine diphosphocholine in patients with vascular dementia. Journal of International Medical Research 19: 330–341, 1991
Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12: 189–198, 1975
Frattola L, Piolti RE, Bassi S, Albizzati MG, Galetti G, et al. Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of the multi-infarct dementia. Current Therapeutic Research 49: 683–693, 1991
Gottfries CG, Bråne G, Steen G. A new rating scale for dementia syndromes. Gerontology 28 (Suppl. 2): 20–31, 1982
Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6: 278–296, 1967
McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34: 939–944, 1984
Parnetti L, Gaiti A, Mecocci P, Gottfries CG, Santucci C. Effect of acetyl-L-carnitine on serum levels of Cortisol and adrenocorticotropic hormone and its clinical effect in patients with senile dementia of Alzheimer type. Dementia 1: 165–169, 1990
Parnetti L, Gottfries CG, Brane G, Buccolieri A, Veneziano V, et al. La scala GBS per la valutazione delle demenze: studio della inter-rater reliability della versione italiana. Giornale di Gerontologia 37: 293–304, 1989
Rai G, Wright G, Scott L, Beston B, Rest J, et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer’s dementia. Current Medical Research and Opinion 11: 638–647, 1990
Reisberg B, Ferris SH De Leon MJ, Crook T. The global deterioration for assessment of primary degenerative dementia. American Journal of Psychiatry 139: 1136–1139, 1982
Rey A. Mémorisation d’une série de 15 mots en 5 répétitions. In L’Examen clinique en psychologie. Paris, Ed Presse Universitaire de France 141: 193, 1958
Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment Geriatric (SCAG). Journal of the American Geriatrics Society 22: 107–113, 1974
Spano PF, Trabucchi M (Eds). αGFC (colina alfoscerato) un farmaco ad azione integrata sulle funzioni neuronali. Stato dell’arte. Basi Razionali della Terapia 20 (Suppl. 1): 1–93, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Parnetti, L., Abate, G., Bartorelli, L. et al. Multicentre Study of l-α-Glyceryl-Phosphorylcholine vs ST200 among Patients with Probable Senile Dementia of Alzheimer’s Type. Drugs & Aging 3, 159–164 (1993). https://doi.org/10.2165/00002512-199303020-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199303020-00006